Vusolimogene Oderparepvec

Phase 3Gene therapy

YYana Najjar

Vusolimogene Oderparepvec is one of 84 biologic programs targeting Metastasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MetastasisActive, not recruiting

AngiosarcomaActive, not recruiting

MelanomaActive, not recruiting

MetastasisPhase 1

Active, not recruiting

AngiosarcomaPhase 2

Active, not recruiting

MelanomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

CC 5013

Bristol-Myers Squibb

Phase 3

3 2

Carboplatin/paclitaxel

AstraZeneca

Phase 3

1 3

HBI-8000

HHUYABIO International, LLC.

Phase 3

1 4

Vusolimogene Oderparepvec

YYana Najjar

Phase 3

1 5

Zelboraf

CConrado Roberto Hoffmann Filho

Preclinical

39 6

Isolated Limb Perfusion

MMemorial Sloan Kettering Cancer Center

Phase 3

2 7

Cancervax Vaccine (CANVAXIN)

CCancerVax Corporation

Phase 3

2 8

Intron a

Merck & Co.

Preclinical

4 9

Opdualag

Bristol-Myers Squibb

Preclinical

3 10

Adjuvant Nivolumab

TThe Netherlands Cancer Institute

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Metastasis

NCT06216938

Q4 2029

Phase 2Recruiting

Angiosarcoma

NCT06898970

Q3 2034

Phase 3Recruiting

Melanoma

NCT06264180

Clinical

Trials by Indication[1]

Melanoma1 trial

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

Recruiting·RReplimune Inc.·Phase 3·NCT06264180·400 enrolled

Angiosarcoma1 trial

Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma

Recruiting·VVarun Monga, MBBS·Phase 2·NCT06898970·18 enrolled

Metastasis1 trial

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

Recruiting·YYana Najjar·Phase 1·NCT06216938·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Vusolimogene Oderparepvec. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vusolimogene Oderparepvec compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vusolimogene Oderparepvec. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yana Najjar company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Highest Phase: Phase 3[1]
Company: YYana Najjar

Vusolimogene Oderparepvec

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2029

Q3 2034

Trials by Indication[1]

Melanoma1 trial

Angiosarcoma1 trial

Metastasis1 trial

References

Drug Info

Quick Facts

Related News